Form 4: Theriva Biologics Director Acquires Stock Options

Jeffrey Alan Wolf, a director of Theriva Biologics, Inc., acquired 25,000 stock options on April 29, 2025, exercisable for common stock.

Summary

• On May 1, 2025, Jeffrey Alan Wolf, a director of Theriva Biologics, Inc. (TOVX), filed a Form 4 indicating a change in beneficial ownership.
• Wolf acquired 25,000 stock options on April 29, 2025, with an exercise price of $1.4144.
• These options vest pro rata on a monthly basis over 12 months, beginning May 1, 2025, and expire on April 29, 2032.
• Following the transaction, Wolf directly owns 25,000 derivative securities (stock options).

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock option grants to a company director. It doesn't inherently convey positive or negative sentiment.

Industry Context

Form 4 filings are standard disclosures required by the SEC when insiders, such as directors and officers, trade in their company's stock. These filings provide transparency to the market regarding insider activity.

Stakeholder Impact

• The acquisition of stock options by a director could be viewed positively by shareholders as it aligns the director's interests with the company's performance.

Key Dates

Keywords

Theriva Biologics, TOVX, Form 4, Stock Options, Beneficial Ownership, Director, Jeffrey Alan Wolf